Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

ABSTRACT:

SUBMITTER: Cerhan JR

PROVIDER: S-EPMC5837578 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Cerhan James R JR Link Brian K BK Habermann Thomas M TM Maurer Matthew J MJ Feldman Andrew L AL Syrbu Sergei I SI Thompson Carrie A CA Farooq Umar U Novak Anne J AJ Slager Susan L SL Allmer Cristine C Lunde Julianne J JJ Macon William R WR Inwards David J DJ Johnston Patrick B PB Micallef Ivana N M INM Nowakowski Grzegorz S GS Ansell Stephen M SM Kay Neil E NE Weiner George J GJ Witzig Thomas E TE

International journal of epidemiology 20171201 6

PMID: 29025017

Similar Datasets

Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.

Project description:The optimal treatment of follicular lymphoma (FL) is not established. Rituximab's value potentially dilutes the impact of chemotherapy on FL. We reviewed 337 cases of FL treated initially with rituximab as monotherapy or with chemotherapy at the University of Iowa/Mayo Clinic from 2002 to 2009, investigating the association between chemotherapy delivery of cyclophosphamide or doxorubicin and survival. With median follow-up duration of 52.7 months, event-free survival (EFS) and overall survival (OS) were similar between the two groups, with a trend toward better EFS in the R-chemotherapy cohort (hazard ratio [HR]=1.24, p=0.28). In the R-chemotherapy group, increased total dose delivery and delivered dose intensity of doxorubicin were associated with improved EFS only in patients who did not receive R-maintenance (HR=0.81; p=0.02 and HR=0.94; p=0.04). Cyclophosphamide delivery was not associated with EFS. Thus, in the immunochemotherapy era, chemotherapy delivery strategy requires re-evaluation.

| S-EPMC4530103 | biostudies-literature

Data Resource Profile: The Manitoba Multigenerational Cohort.